Table 2.
Characteristics of HCV/HIV co-infected patients
| CD4 ≤ 250 (n = 33) | CD4 > 250 (n = 72) | P-value | |
|---|---|---|---|
| Age (years) | 41 ± 6 | 41 ± 8 | 0.98 |
| Male gender, n (%) | 30 (90.9) | 59 (81.9) | 0.24 |
| Race, n (%) | |||
| White | 23 (69.7) | 53 (73.6) | 0.75 |
| Black | 6 (18.2) | 14 (19.4) | |
| Hispanic | 4 (12.1) | 2 (2.8) | |
| Other | 0 | 3 (4.2) | |
| HCV genotype (%) | |||
| Genotype 1 | 28 (84.9) | 50 (69.5) | 0.08 |
| Genotype 2 | 3 (9.1) | 11 (15.3) | |
| Genotype 3 | 1 (3.0) | 7 (9.7) | |
| Other | 1 (3.0) | 4 (5.5) | |
| AST (IU/mL) | 63.91 ± 32.21 | 60.75 ± 36.72 | 0.67 |
| ALT (IU/mL) | 100.94 ± 105.08 | 84.53 ± 56.22 | 0.30 |
| Bilirubin (mg/dL) | 0.93 ± 0.58 | 0.84 ± 0.36 | 0.32 |
| Albumin (g/dL) | 3.86 ± 0.43 | 3.75 ± 0.32 | 0.16 |
| Platelet count (109/L) | 197.12 ± 59.49 | 210.04 ± 66.37 | 0.34 |
| INR | 0.99 ± 0.09 | 0.99 ± 0.08 | 0.79 |
| APRI | 0.84 ± 0.56 | 0.78 ± 0.65 | 0.65 |
| HCV RNA (log10) | 6.3 ± 0.8 | 6.2 ± 0.8 | 0.59 |
| HAART, n (%) | 25 (75.8) | 48 (66.7) | 0.35 |
| HIV RNA (log10) | 4.83 ± 5.29 | 4.18 + 4.58 | 0.03 |
| Undetectable HIV RNA, n (%) | 12 (36.4) | 30 (41.7) | 0.76 |
| CD4+ T-cell count (cells/mm3) | 170 ± 70 | 550 ± 240 | <0.001 |
| Liver biopsy length (mm) | 21 ± 9 | 19 ± 9 | 0.35 |
| Stage, n (%) | |||
| Stage 0 | 0 | 1 (1.4) | 0.69 |
| Stage 1 | 7 (21.2) | 12 (16.7) | |
| Stage 2 | 18 (54.6) | 43 (59.7) | |
| Stage 3 | 4 (12.1) | 12 (16.7) | |
| Stage 4 | 4 (12.1) | 4 (5.5) | |
Data presented as mean ± s.d. or n (%).
APRI, AST to platelet ratio index; HAART, highly active anti-retroviral therapy.